XASXTRP
Market cap10mUSD
Jan 03, Last price
0.27AUD
1D
0.00%
1Q
-21.74%
IPO
-58.14%
Name
Tissue Repair Ltd
Chart & Performance
P/E
—
P/S
107.24
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
152k
+4,849.28%
Net income
-4m
L-0.87%
CFO
-5m
L+16.35%
Profile
Tissue Repair Ltd, a clinical stage biopharmaceutical company, developing advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia. It is developing TR-987 and other dressing/matrices, including Glucoprime technology for the treatment of chronic wounds, burns, and other complex wounds; and TR Pro+ for aftercare of minimally invasive cosmetic procedures, as well as other products for veterinary, new bandage, scaffold products, and other therapeutic indications. The company was incorporated in 2012 and is headquartered in Sydney, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | |
| Income | |||||
Revenues | 152 4,849.28% | 3 -98.21% | 172 12.63% | ||
Cost of revenue | 5,891 | 4,931 | 3,293 | ||
Unusual Expense (Income) | |||||
NOPBT | (5,739) | (4,928) | (3,121) | ||
NOPBT Margin | |||||
Operating Taxes | (969) | (1,429) | |||
Tax Rate | |||||
NOPAT | (5,739) | (3,959) | (1,692) | ||
Net income | (4,138) -0.87% | (4,174) -38.95% | (6,838) 647.09% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 21,361 | ||||
BB yield | -141.31% | ||||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | 14 | 7 | 864 | ||
Net debt | (16,441) | (21,396) | (25,455) | ||
| Cash flow | |||||
Cash from operating activities | (4,951) | (4,255) | (3,966) | ||
CAPEX | (3) | (2) | (4) | ||
Cash from investing activities | (3) | (2) | (4) | ||
Cash from financing activities | 21,361 | ||||
FCF | (6,858) | (4,449) | (1,694) | ||
| Balance | |||||
Cash | 16,441 | 21,396 | 25,455 | ||
Long term investments | |||||
Excess cash | 16,433 | 21,396 | 25,447 | ||
Stockholders' equity | 18,039 | 21,882 | 25,338 | ||
Invested Capital | 1,619 | 492 | 864 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 60,465 | 60,465 | 60,465 | ||
Price | 0.23 -16.67% | 0.27 8.00% | 0.25 | ||
Market cap | 13,605 -16.67% | 16,326 8.00% | 15,116 | ||
EV | (2,836) | (5,071) | (10,339) | ||
EBITDA | (5,737) | (4,925) | (3,119) | ||
EV/EBITDA | 0.49 | 1.03 | 3.31 | ||
Interest | 3 | ||||
Interest/NOPBT | |||||